|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FISH, ALL, +4, +10, +17, TC
Test Code12636
CPT Codes
88271 (x3), 88275<br>Restricted Client Code - Tech Only
Preferred Specimen
3 mL bone marrow or 5 mL whole blood collected in sodium heparin (green-top) tube
Minimum Volume
1 mL bone marrow • 3 mL whole blood
Other Acceptable Specimens
Bone marrow or whole blood collected in: sodium heparin (royal blue-top) tube, or sodium heparin lead-free (tan-top) tube
Instructions
Clinical history and reason for referral are required with test order. Prior therapy and bone marrow transplant history should be provided with test order.
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Transport Temperature
Room temperature
Specimen Stability
See Instructions
Methodology
Fluorescence in situ Hybridization
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Daily; Report available: 5 days
Clinical Significance
100-300 interphase cells are microscopically analyzed to enumerate the centromeric probe signals for chromosomes 4, 10, and 17 in each cell.
Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing nearly one third of all pediatric cancers. The annual incidence of ALL is about 30 cases per million people, with a peak incidence in children aged 2-5 years. Various abnormalities have been described and most of them are associated with a determined prognostic outcome. The most common (25% of cases) and most favorable chromosome finding is the hyperdiploid, especially gains of chromosomes 4, 10, and 17.
Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing nearly one third of all pediatric cancers. The annual incidence of ALL is about 30 cases per million people, with a peak incidence in children aged 2-5 years. Various abnormalities have been described and most of them are associated with a determined prognostic outcome. The most common (25% of cases) and most favorable chromosome finding is the hyperdiploid, especially gains of chromosomes 4, 10, and 17.
